Situation analysis study on nanomedicines regulation and assessment practices in Zazibona active countries

Abstract

Nanomedicines are loosely defined as medicines that seek to apply nanotechnology. Currently, nanomedicines are available for clinical use, including treatments for cancer, high cholesterol, hepatitis, COVID-19 vaccination, among other uses (Patra et al., 2018; Gao et al., 2021). Most of the nanomedicines meet the definition of medicines according to various national legislations. Consequently, these products are regulated as medicines. Nanomedicines present major differences in biological details and increased complexity of clinical use. They integrate different technology subsets from therapeutics to imaging and integrated non-invasive diagnosis (Gaspar, 2007). These complexities require extra regulatory effort.